JAK2 and gastric cancer: In contrast with the CALM2 group, the JAK2 or HIF-1 inhibitor considerably alleviated the effects of CALM2 on GC cells in the processes covering proliferation (Figures 7B, C), migration (Figure 7D), invasion (Figure 7E), and GC cell EMT progression (Figure 7F).